Metadata supporting the article: Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1
Creators: name: Li, Xiahui
name: Li, Shujing
name: Li, Bowen
name: Li, Yanan
name: Aman, Sattout
name: Xia, Kangkai
name: Yang, Yuxi
name: Ahmad, Bashir
name: Wu, Huijian
Publisher: name: figshare
Year: 2021
Subjects: Biological Sciences not elsewhere classified
Biological Techniques
Cancer
Medicine
Cancer Cell Biology
Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics)

description: E74-like ETS transcription factor 5
(ELF5), also known as epithelium-specific ETS transcription factor 2, belongs
to the E26 transformation-specific (ETS) transcription factor family and is
characterized by a highly conserved DNA binding domain (DBD) responsible for
recognizing the GGA[AT] core sequence in its target genes. A sustained increase in ELF5 expression has
been demonstrated in endocrine-resistant breast cancers and basal-like subtype
breast cancer. ELF5 also drives lung metastasis via the recruitment of GR1+ CD11b+
myeloid-derived suppressor cells in luminal breast cancer. The functional role
and regulatory mechanism of ELF5 in cancer tumorigenesis and progression are
still largely unclear. The function of a transcription factor is often controlled
by post-translational modifications (PTMs). In this article, the authors studied
the protein interactome of the histone acetyltransferase p300, and the effects of post translational
modifications of ELF5 (a p300- interacting protein) on cancer progression.<b></b><br>

<b>Data access: </b>The mass-spectrometry based proteomics data (p300-interacting
proteins in human breast cancer cells) generated during this study, are
publicly available in the PRIDE repository: https://identifiers.org/pride.project:PXD023240.
All other datasets generated and analysed during this study (luciferase reporter assay data, immunoprecipitation and immunofluorescence
assay data, xenograft model data, GST-pulldown assay data, <i>in vitro</i> acetylation
and deacetylation assay data, chromatin Immunoprecipitation assay data, cell
proliferation assay data, cell cycle assay data and immunohistochemistry data)
will be made available on reasonable request from the corresponding author Dr. Huijian Wu, email address: wuhj@dlut.edu.cn. Uncropped Western blots
are part of the supplementary files.<br>

<b>Study approval and consent for use of human tissue:</b> All animal experiments and immunohistochemical analysis were approved
by the Ethics Committee for Biology and Medical Science of Dalian University of
Technology. All individuals who donated the tissues for this study gave their
consent in written form.<br>

<b>Study aims and methodology: </b>Currently,<b> </b>there is no study concerning the effects
of post-translational modifications (PTMs) on the regulation of ELF5. This
study aimed to identify the protein interactome of the histone acetyltransferase
p300, and investigate the effects of post
translational modifications of the transcription factor ELF5 (a p300- interacting
protein) on cancer progression.<b></b>

Cell lines MCF7,
T47D, HEK293T, HeLa were used in the current study. The following techniques
and assays are described in more detail in the related article: plasmids and reagents
used, cell culture and transfection, chemicals used, luciferase reporter assay,
immunoprecipitation, western blot, immunofluorescence assay, human breast
cancer xenograft model experiments, GST-pulldown assay, <i>in vitro</i> acetylation and
deacetylation assay, cell proliferation assay, cell cycle assay, construction
of mutants and site-directed mutagenesis, immunohistochemical staining assay,
gene silencing, mass spectrometry, identification of acetylation site by
LC-MS/MS analysis, and statistical analysis.<br>

 

<b>Data supporting the findings in the article: </b>The file<b> Li, X. et al.xlsx </b>includes
a list of all the datasets generated and analysed during the study.<br>

 

<b>Software needed to access data</b>: The flow cytometry (.fcs) data files can be accessed using the CytExpert
software.